ProteinQure is a biotech company focused on the design of novel exotic peptides with broad therapeutic applications. Powered by atomic-level simulations and artificial intelligence, it designs dynamic peptides to deliver drugs straight to their target sites. The company's lead therapeutic PQ203 for TOP1-resistant triple-negative breast cancer entered Phase I trials in the US and Canada. The company has various anti-cancer drugs in its pipeline.